1 / 6

New Drug for Prostate Cancer Gets FDA Nod

New Drug for Prostate Cancer Gets FDA Nod. http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html?ref=policy&_r=0. Andrew Pollack The New York Times August 31, 2012. Prostate Cancer. Expected 241,000 new cases this year and 28,000 deaths

cassandra-brady
Download Presentation

New Drug for Prostate Cancer Gets FDA Nod

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. New Drug for Prostate Cancer Gets FDA Nod http://www.nytimes.com/2012/09/01/business/fda-approves-prostate-cancer-drug.html?ref=policy&_r=0 Andrew Pollack The New York Times August 31, 2012

  2. Prostate Cancer • Expected 241,000 new cases this year and 28,000 deaths • Lupron is the usual treatment, which induces a chemical castration (suppressed testosterone production). • Before 2004, docetaxel (chemotherapy) was the only option for advanced prostate cancer. • Other options: Jevtana, Provenge, and Zytiga

  3. Xtandi (enzalutamide) • Life-prolonging drug for men with late-stage prostate cancer • Blocks testosterone from enhancing cancer growth • Clinical trials: • Median of 18.4 months (with Xtandi) • Median of 13.6 months (with placebo) • Cost is $7,450/month (higher than expected)

  4. FDA Approval • Approval after only a 3-month review • Priority Review Program is usually 6 months. • After a long period of no new treatment options, Xtandi is one of several to come to the market within the last 2 years. • Most worrisome side effect are seizures, which were found by 1% of men in the clinical trial.

  5. Xtandi vs. Zytiga • Both are pills (previous drugs are injections) • Both aimed at men with late-stage prostate cancer that has spread. • Both approved for men who have already tried docetaxel. • No head-to-head clinical trials. • Advantage for Xtandi-does not have to be given with prednisone as Zytiga does.

  6. The Economics Price PM MC D MR QC QM Quantity PC

More Related